

Michael Soyka

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2391677/michael-soyka-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

85
papers

2,742
citations

25
h-index

51
g-index

89
ext. papers

3,385
ext. citations

5.8
avg, IF

5.9
L-index

#	Paper	IF	Citations
85	A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis. <i>Nature Genetics</i> , 2015 , 47, 1443-8	36.3	303
84	Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 320, 815-824	27.4	205
83	Substance misuse, psychiatric disorder and violent and disturbed behaviour. <i>British Journal of Psychiatry</i> , 2000 , 176, 345-50	5.4	203
82	Acamprosate for alcohol dependence. <i>The Cochrane Library</i> , 2010 , CD004332	5.2	160
81	Treatment of Benzodiazepine Dependence. <i>New England Journal of Medicine</i> , 2017 , 376, 1147-1157	59.2	156
80	Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: results from a randomized study. <i>International Journal of Neuropsychopharmacology</i> , 2008 , 11, 641-53	5.8	111
79	Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: results from a placebo-controlled, double-blind trial. <i>Journal of Clinical Psychopharmacology</i> , 2008 , 28, 317-24	1.7	92
78	Neurobiology of aggression and violence in schizophrenia. <i>Schizophrenia Bulletin</i> , 2011 , 37, 913-20	1.3	78
77	Association of the OPRM1 Variant rs1799971 (A118G) with Non-Specific Liability to Substance Dependence in a Collaborative de novo Meta-Analysis of European-Ancestry Cohorts. <i>Behavior Genetics</i> , 2016 , 46, 151-69	3.2	77
76	The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorders. Part 2: Opioid dependence. <i>World Journal of Biological Psychiatry</i> , 2011 , 12, 160-87	3.8	73
75	Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 1987-1999	4	67
74	Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis. <i>Gut</i> , 2019 , 68, 1099-1107	19.2	62
73	Pharmacotherapy of alcoholism - an update on approved and off-label medications. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 1187-1199	4	60
72	Cognitive functioning during methadone and buprenorphine treatment: results of a randomized clinical trial. <i>Journal of Clinical Psychopharmacology</i> , 2008 , 28, 699-703	1.7	56
71	Genome-wide association study identifies inversion in the locus to modify risk for alcoholic and non-alcoholic chronic pancreatitis. <i>Gut</i> , 2018 , 67, 1855-1863	19.2	54
70	Alcohol use disorders in opioid maintenance therapy: prevalence, clinical correlates and treatment. <i>European Addiction Research</i> , 2015 , 21, 78-87	4.6	48
69	One-year mortality rates of patients receiving methadone and buprenorphine maintenance therapy: a nationally representative cohort study in 2694 patients. <i>Journal of Clinical Psychopharmacology</i> , 2006 , 26, 657-60	1.7	46

68	Less impairment on one portion of a driving-relevant psychomotor battery in buprenorphine-maintained than in methadone-maintained patients: results of a randomized clinical trial. <i>Journal of Clinical Psychopharmacology</i> , 2005 , 25, 490-3	1.7	45
67	Psychopathology in dual diagnosis and non-addicted schizophrenics--are there differences?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2001 , 251, 232-8	5.1	42
66	Effects of haloperidol and risperidone on psychomotor performance relevant to driving ability in schizophrenic patients compared to healthy controls. <i>Journal of Psychiatric Research</i> , 2005 , 39, 101-8	5.2	39
65	New developments in the management of opioid dependence: focus on sublingual buprenorphine-naloxone. <i>Substance Abuse and Rehabilitation</i> , 2015 , 6, 1-14	5.5	34
64	A common polymorphism in the NCAN gene is associated with hepatocellular carcinoma in alcoholic liver disease. <i>Journal of Hepatology</i> , 2014 , 61, 1073-9	13.4	28
63	Nalmefene for the treatment of alcohol use disorders: recent data and clinical potential. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 619-26	4	28
62	Delinquency and criminal offenses in former schizophrenic inpatients 7-12 years following discharge. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2004 , 254, 289-94	5.1	26
61	Flupenthixol in relapse prevention in schizophrenics with comorbid alcoholism: results from an open clinical study. <i>European Addiction Research</i> , 2003 , 9, 65-72	4.6	26
60	Nalmefene for the treatment of alcohol dependence: a current update. <i>International Journal of Neuropsychopharmacology</i> , 2014 , 17, 675-84	5.8	25
59	A comparison of cognitive function in patients under maintenance treatment with heroin, methadone, or buprenorphine and healthy controls: an open pilot study. <i>American Journal of Drug and Alcohol Abuse</i> , 2011 , 37, 497-508	3.7	24
58	Treatment-refractory substance use disorder: Focus on alcohol, opioids, and cocaine. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016 , 70, 148-61	5.5	23
57	Use of acamprosate and opioid antagonists in the treatment of alcohol dependence: a European perspective. <i>American Journal on Addictions</i> , 2003 , 12, s69-s80	3.7	23
56	Baclofen for alcohol use disorder. <i>The Cochrane Library</i> , 2018 , 11, CD012557	5.2	23
55	Cognitive and socio-cognitive functioning of chronic non-medical prescription opioid users. <i>Psychopharmacology</i> , 2018 , 235, 3451-3464	4.7	23
54	Effects of stimulant drug use on the dopaminergic system: A systematic review and meta-analysis of in vivo neuroimaging studies. <i>European Psychiatry</i> , 2019 , 59, 15-24	6	21
53	Criminal behavior in opioid-dependent patients before and during maintenance therapy: 6-year follow-up of a nationally representative cohort sample. <i>Journal of Forensic Sciences</i> , 2012 , 57, 1524-30	1.8	20
52	Genome-Wide Association Study for Alcohol-Related Cirrhosis Identifies Risk Loci in MARC1 and HNRNPUL1. <i>Gastroenterology</i> , 2020 , 159, 1276-1289.e7	13.3	19
51	Cognitive Deficits in Methamphetamine Users: How Strong is The Evidence?. <i>Pharmacopsychiatry</i> , 2018 , 51, 243-250	2	19

50	Cognitive function in short- and long-term substitution treatment: Are there differences?. <i>World Journal of Biological Psychiatry</i> , 2010 , 11, 400-408	3.8	19
49	Relapse Prevention in Alcoholism : Recent Advances and Future Possibilities. <i>CNS Drugs</i> , 1997 , 7, 313-276.7	6.7	19
48	Use of acamprosate and different kinds of psychosocial support in relapse prevention of alcoholism. Results from a non-blind, multicentre study. <i>Drugs in R and D</i> , 2002 , 3, 1-12	3.4	19
47	Effects of sedative drug use on the dopamine system: a systematic review and meta-analysis of in vivo neuroimaging studies. <i>Neuropsychopharmacology</i> , 2019 , 44, 660-667	8.7	19
46	A combination of carbamazepine/tiaprider in outpatient alcohol detoxification. Results from an open clinical study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2002 , 252, 197-200	5.1	18
45	Genome-wide Association Study and Meta-analysis on Alcohol-Associated Liver Cirrhosis Identifies Genetic Risk Factors. <i>Hepatology</i> , 2021 , 73, 1920-1931	11.2	18
44	Buprenorphine use in pregnant opioid users: a critical review. <i>CNS Drugs</i> , 2013 , 27, 653-62	6.7	17
43	Why should addiction medicine be an attractive field for young physicians?. <i>Addiction</i> , 2009 , 104, 169-72.4.6	4.6	16
42	Treatment of alcohol withdrawal syndrome with a combination of tiaprider/carbamazepine: results of a pooled analysis in 540 patients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2006 , 256, 395-401	5.1	16
41	Outpatient alcohol detoxification: implementation efficacy and outcome effectiveness of a model project. <i>European Addiction Research</i> , 2004 , 10, 180-7	4.6	16
40	Thalamic hypofunction in alcohol hallucinosis: FDG PET findings. <i>Psychiatry Research - Neuroimaging</i> , 2005 , 139, 259-62	2.9	15
39	Dual Diagnosis in Patients with Schizophrenia. <i>CNS Drugs</i> , 1996 , 5, 414-425	6.7	15
38	Prevalence of delusional jealousy in psychiatric disorders. <i>Journal of Forensic Sciences</i> , 2011 , 56, 450-2	1.8	14
37	PET and SPECT findings in alcohol hallucinosis: case report and super-brief review of the pathophysiology of this syndrome. <i>World Journal of Biological Psychiatry</i> , 2000 , 1, 215-8	3.8	14
36	XRCC5 as a risk gene for alcohol dependence: evidence from a genome-wide gene-set-based analysis and follow-up studies in <i>Drosophila</i> and humans. <i>Neuropsychopharmacology</i> , 2015 , 40, 361-71	8.7	12
35	L-dopa abuse in a patient with former alcoholism. <i>Addiction</i> , 1992 , 87, 117-8	4.6	12
34	Treatment of opioid dependence with buprenorphine: current update. <i>Dialogues in Clinical Neuroscience</i> , 2017 , 19, 299-308	5.7	12
33	Val158Met COMT polymorphism and risk of aggression in alcohol dependence. <i>Addiction Biology</i> , 2015 , 20, 197-204	4.6	10

32	Methamphetamine withdrawal and the restoration of cognitive functions - a study over a course of 6 months abstinence. <i>Psychiatry Research</i> , 2019 , 281, 112599	9.9	9
31	Serotonin and Dopamine Candidate Gene Variants and Alcohol- and Non-Alcohol-Related Aggression. <i>Alcohol and Alcoholism</i> , 2015 , 50, 690-9	3.5	8
30	Buprenorphine-naloxone treatment in opioid dependence and risk of liver enzyme elevation: results from a 12-month observational study. <i>American Journal on Addictions</i> , 2014 , 23, 563-9	3.7	8
29	Buprenorphine and buprenorphine/naloxone soluble-film for treatment of opioid dependence. <i>Expert Opinion on Drug Delivery</i> , 2012 , 9, 1409-17	8	8
28	Feasibility and safety of transfer from racemic methadone to (R)-methadone in primary care: clinical results from an open study. <i>World Journal of Biological Psychiatry</i> , 2009 , 10, 217-24	3.8	8
27	To substitute or not substitute optimal tactics for the management of benzodiazepine dependence. <i>Addiction</i> , 2010 , 105, 1876-7	4.6	7
26	Obesity, Diabetes, Coffee, Tea, and Cannabis Use Alter Risk for Alcohol-Related Cirrhosis in 2 Large Cohorts of High-Risk Drinkers. <i>American Journal of Gastroenterology</i> , 2021 , 116, 106-115	0.7	7
25	Pain management in opioid maintenance treatment. <i>Expert Opinion on Pharmacotherapy</i> , 2019 , 20, 1993-2005	7	6
24	Buprenorphine and buprenorphine/naloxone intoxication in children - how strong is the risk?. <i>Current Drug Abuse Reviews</i> , 2013 , 6, 63-70		6
23	Psychomotor Performance Under Neuroleptic Treatment in Schizophrenia. <i>Zeitschrift für Neuropsychologie = Journal of Neuropsychology</i> , 2001 , 12, 49-53	0.5	6
22	Driving ability in schizophrenic patients: effects of neuroleptics. <i>International Journal of Psychiatry in Clinical Practice</i> , 2005 , 9, 168-74	2.4	5
21	Short-term changes in global methylation and hydroxymethylation during alcohol detoxification. <i>European Neuropsychopharmacology</i> , 2019 , 29, 897-903	1.2	4
20	Buprenorphine-naloxone buccal soluble film for the treatment of opioid dependence: current update. <i>Expert Opinion on Drug Delivery</i> , 2015 , 12, 339-47	8	4
19	Outcome Assessment in Trials of Pharmacological Treatments for Alcohol Use Disorders: Fair and Strict Testing. <i>CNS Drugs</i> , 2019 , 33, 649-657	6.7	4
18	A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers. <i>Journal of Hepatology</i> , 2021 ,	13.4	4
17	Ranking the Harm of Psychoactive Drugs Including Prescription Analgesics to Users and Others-A Perspective of German Addiction Medicine Experts. <i>Frontiers in Psychiatry</i> , 2020 , 11, 592199	5	4
16	Abstinence or maintenance treatment in substance use disorders?. <i>Addiction</i> , 2016 , 111, 775-6	4.6	4
15	The Impact of the Opioid Antagonist Naloxone on Experimentally Induced Craving in Nicotine-Dependent Individuals. <i>European Addiction Research</i> , 2018 , 24, 255-265	4.6	4

14	Pharmacological trials in alcoholics—Some comments on methodological problems. <i>Addiction</i> , 1997 , 92, 956-958	4.6	2
13	Propofol dependency. <i>Addiction</i> , 1997 , 92, 1369-1370	4.6	2
12	Transition from methadone to subcutaneous buprenorphine depot in patients with opioid use disorder in custodial setting - a case series. <i>American Journal of Drug and Alcohol Abuse</i> , 2021 , 47, 599-604	3.7	2
11	Commentary on Hser et al. (2014): to retain or not to retain—open questions in opioid maintenance therapy. <i>Addiction</i> , 2014 , 109, 88-9	4.6	1
10	Transition From Full Mu Opioid Agonists to Buprenorphine in Opioid Dependent Patients—A Critical Review. <i>Frontiers in Pharmacology</i> , 2021 , 12, 718811	5.6	1
9	A genetic variant in toll-like receptor 5 is linked to chemokine levels and hepatocellular carcinoma in steatohepatitis. <i>Liver International</i> , 2021 , 41, 2139-2148	7.9	0
8	Psychiatric Comorbidity and Stress in Medical Students Using Neuroenhancers.. <i>Frontiers in Psychiatry</i> , 2021 , 12, 771126	5	0
7	FURTHER REFLECTIONS ON "WHY SHOULD ADDICTION MEDICINE BE AN ATTRACTIVE FIELD FOR YOUNG PHYSICIANS?" <i>Addiction</i> , 2009 , 104, 177-178	4.6	
6	Pharmacotherapies of Opioid Detoxification—An Evaluation of Different Pharmacotherapeutical Strategies. <i>Alcoholism Treatment Quarterly</i> , 1999 , 17, 47-53	1.2	
5	Pathophysiological mechanisms possibly involved in the development of alcohol hallucinosis. <i>Addiction</i> , 1995 , 90, 289-290	4.6	
4	Substance abuse in schizophrenics. <i>British Journal of Psychiatry</i> , 1994 , 165, 836-7	5.4	
3	Pharmacotherapy of Alcohol Use Disorders 2020 , 1-17		
2	Pharmakologische Rückfallprophylaxe der Alkoholabhängigkeit. <i>Nervenheilkunde</i> , 2021 , 40, 628-635	0.3	
1	Recent advances in the treatment of opioid use disorders—focus on long-acting buprenorphine formulations. <i>World Journal of Psychiatry</i> , 2021 , 11, 543-552	3	